Catalyst Biosciences to Participate in Two Upcoming Investor Conferences
June 10 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that
members of its executive management team will participate in
fireside chats at the two investor conferences in June: Raymond
James Human Health Innovation Conference and the JMP Securities
Life Sciences Conference.
JMP Securities Life Sciences Conference
Date: |
Wednesday, June 16, 2021 |
Time: |
1:30 PM Eastern Time |
Webcast: |
JMP Webcast |
Raymond James Human Health Innovation
Conference
Date: |
Wednesday, June 23, 2021 |
Time: |
11:20 AM Eastern Time |
Webcast: |
RJ Webcast |
An archived webcast of the presentations will be available for
90 days on the Events and Presentations section of the
Company’s website.
About Catalyst Biosciences, the Protease
Medicines companyCatalyst is a research and clinical
development biopharmaceutical company focused on addressing unmet
medical needs in rare disorders of the complement and coagulation
systems. Our protease engineering platform has generated two
late-stage clinical programs, including MarzAA, a subcutaneously
(SQ) administered next-generation engineered coagulation Factor
VIIa (FVIIa) for the treatment of episodic bleeding in subjects
with rare bleeding disorders. Our complement pipeline includes a
preclinical C3-degrader program licensed to Biogen for dry
age-related macular degeneration, an improved complement factor I
protease for SQ replacement therapy in patients with CFI deficiency
and C4b-degraders designed to target disorders of the classical
complement pathway as well as other complement programs in
development.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties. Forward-looking statements
include statements about, the potential benefits of products based
on Catalyst’s engineered protease platform, and the Company’s
collaboration with Biogen for the development and commercialization
of a pre-clinical C3-degrader program dry age-related macular
degeneration. Actual results or events could differ materially from
the plans, intentions, expectations and projections disclosed in
the forward-looking statements. Various important factors could
cause actual results or events to differ materially, including, but
not limited to, the risk that trials and studies may be delayed as
a result of COVID-19, competitive products and other factors, that
trials may not have satisfactory outcomes, that additional human
trials will not replicate the results from earlier trials, that
potential adverse effects may arise from the testing or use of
MarzAA, including the generation of neutralizing antibodies, the
risk that costs required to develop or manufacture the Company's
products will be higher than anticipated, including as a result of
delays in trial enrollment, development and manufacturing resulting
from COVID-19 and other factors, the risk that Biogen will
terminate Catalyst's agreement, competition and other risks
described in the "Risk Factors" section of the Company's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on May 6, 2021, and in other filings with
the Securities and Exchange Commission. The Company does not
assume any obligation to update any forward-looking statements,
except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024